Roumell Asset Management LLC decreased its position in Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) by 60.7% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 101,399 shares of the specialty pharmaceutical company’s stock after selling 156,349 shares during the quarter. Paratek Pharmaceuticals accounts for 6.0% of Roumell Asset Management LLC’s portfolio, making the stock its 8th largest position. Roumell Asset Management LLC owned about 0.36% of Paratek Pharmaceuticals worth $2,545,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in PRTK. TIAA CREF Investment Management LLC lifted its position in Paratek Pharmaceuticals by 11.7% in the first quarter. TIAA CREF Investment Management LLC now owns 75,076 shares of the specialty pharmaceutical company’s stock valued at $1,445,000 after purchasing an additional 7,844 shares during the last quarter. Vanguard Group Inc. lifted its position in Paratek Pharmaceuticals by 9.5% in the first quarter. Vanguard Group Inc. now owns 724,300 shares of the specialty pharmaceutical company’s stock valued at $13,942,000 after purchasing an additional 63,121 shares during the last quarter. Geode Capital Management LLC lifted its position in Paratek Pharmaceuticals by 10.7% in the first quarter. Geode Capital Management LLC now owns 148,962 shares of the specialty pharmaceutical company’s stock valued at $2,867,000 after purchasing an additional 14,392 shares during the last quarter. Morgan Stanley lifted its position in Paratek Pharmaceuticals by 160.2% in the first quarter. Morgan Stanley now owns 154,693 shares of the specialty pharmaceutical company’s stock valued at $2,978,000 after purchasing an additional 95,243 shares during the last quarter. Finally, Credit Suisse AG lifted its position in Paratek Pharmaceuticals by 36.6% in the first quarter. Credit Suisse AG now owns 18,110 shares of the specialty pharmaceutical company’s stock valued at $349,000 after purchasing an additional 4,853 shares during the last quarter. Institutional investors own 84.30% of the company’s stock.

Several analysts have weighed in on PRTK shares. Zacks Investment Research upgraded Paratek Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 1st. BidaskClub downgraded Paratek Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Saturday. Cantor Fitzgerald set a $50.00 target price on Paratek Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, October 17th. Raymond James Financial restated a “strong-buy” rating and set a $36.00 target price on shares of Paratek Pharmaceuticals in a report on Thursday, August 24th. Finally, ValuEngine downgraded Paratek Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, September 18th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. Paratek Pharmaceuticals has an average rating of “Buy” and a consensus price target of $40.00.

Paratek Pharmaceuticals, Inc. (PRTK) opened at $18.55 on Tuesday. The company has a current ratio of 10.53, a quick ratio of 10.53 and a debt-to-equity ratio of 0.49. Paratek Pharmaceuticals, Inc. has a twelve month low of $13.10 and a twelve month high of $29.00.

TRADEMARK VIOLATION NOTICE: “Roumell Asset Management LLC Has $2.55 Million Position in Paratek Pharmaceuticals, Inc. (PRTK)” was first posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another site, it was copied illegally and reposted in violation of international copyright and trademark laws. The correct version of this story can be viewed at https://theolympiareport.com/2017/12/05/roumell-asset-management-llc-has-2-55-million-position-in-paratek-pharmaceuticals-inc-prtk.html.

Paratek Pharmaceuticals Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Want to see what other hedge funds are holding PRTK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK).

Institutional Ownership by Quarter for Paratek Pharmaceuticals (NASDAQ:PRTK)

Receive News & Ratings for Paratek Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.